Information  X 
Enter a valid email address

Velocys PLC (VLS)

  Print          Annual reports

Tuesday 21 July, 2020

Velocys PLC

Disclosure re Directors' Participation in Placing

RNS Number : 5465T
Velocys PLC
21 July 2020
 

News release

Velocys plc

("Velocys" or the "Company")

21 July 2020

Disclosure re directors' participation in the placing and open offer

 

Velocys plc (VLS.L), the sustainable fuels technology company (the "Company" ) , announces that, further to the announcement on 25 June 2020 advising the proposed subscription by the directors of the Company of an aggregate of 1,200,000 new ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 5p per new Ordinary Share as part of the placing, and following the subscription by certain directors of the Company for an aggregate of 96,487 new Ordinary Shares at a price of 5p per new Ordinary Share as part of the open offer announced by the Company on 24 June 2020 and 25 June 2020, the corresponding disclosure forms summarised below have today been submitted online to the FCA in relation to these transactions.

 

The resultant interests of the relevant directors and persons closely associated with them in the shares of the Company are:

 

Director

Number of Ordinary Shares held

Percentage of entire issued share capital

1.  Philip Holland

1,203,118

0.11%

2.  Henrik Wareborn

2,118,445

0.20%

3.  Andrew Morris

847,817

0.08%

4.  Sandra Shaw

551,091

0.05%

5.  Darran Messem

433,333

0.04%

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1.  Philip Holland

2.  Henrik Wareborn

3.  Andrew Morris

4.  Cecil Shaw

5.  Darran Messem

2.

Reason for the notification

a)

Position / status

1.  Non-executive Chairman

2.  Chief Executive Officer

3.  Chief Financial Officer

4.  Person closely associated with a PDMR - Sandra Shaw, Non-executive Director

5.  Non-executive Director

b)

Initial notification / amendment

Initial notification

3.

Details of issuer

a)

Name

Velocys plc

b)

LEI

549300KGMQV70HA5Y715

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares of 1p each

 

1.  GB00B11SZ269

2.  GB00B11SZ269

3.  GB00B11SZ269

4.  GB00B11SZ269

5.  GB00B11SZ269

 

b)

Nature of the transaction

Subscription for new Ordinary Shares.

The transaction is not linked to the exercise of a share option programme.

c)

Price(s) and volume(s)

Director/PCA Name

Price

Volume

1.  Philip Holland

5p

230,224

2.  Henrik Wareborn

5p

451,779

3.  Andrew Morris

5p

414,484

4.  Cecil Shaw

5p

100,000

5.  Darran Messem

5p

100,000

d)

Aggregated information

Aggregated volume Price

  N/A

e)

Date of the transactions

Director/PCA Name

Date of Transaction

1.  Philip Holland

2020-07-16 GMT

2.  Henrik Wareborn

2020-07-16 GMT

3.  Andrew Morris

2020-07-16 GMT

4.  Cecil Shaw

2020-07-16 GMT

5.  Darran Messem

2020-07-16 GMT

f)

Place of the transaction

Outside a trading venue 

 

 

 

- Ends -

For further information, please contact:

Velocys

Henrik Wareborn, CEO

Andrew Morris, CFO

Lak Siriwardene, Head of Communications & Sustainability

 

+44 1865 800821

 

Numis Securities (Nomad and joint broker)

Stuart Skinner

Louis McKeeve

 

+44 20 7260 1000

Canaccord Genuity (Joint broker)

Henry Fitzgerald-O'Connor

James Asensio

+44 20 7523 8000

 

 

 

Turner Pope Investments (Joint broker)

James Pope

 

Radnor Capital (Investor relations)

Joshua Cryer

Iain Daly

+44 20 3657 0050

 

 

+44 20 3897 1830

 

 

Field Consulting (PR)

Robert Jeffery

 

+44 20 7096 7730

 

 

www.velocys.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHURABRRSUBUAR

a d v e r t i s e m e n t